- CMC Consulting & Advanced Biologics
Engineering Confidence from Lab to Launch
Specialized in ADC Development, CMC Strategy, and Antibody-Drug Conjugate Programs, from early development through commercial readiness.
100%
ADC ExpertiseAntibody-Drug Conjugate Expertise Across Development and CMC
Specialized ADC support from preclinical planning through commercial readiness
DES Pharma supports ADC programs across cleavable and non-cleavable linker systems, auristatin and maytansinoid payload classes, and both conventional and site-specific conjugation strategies. We help sponsors move from early product concept to a development path that works for manufacturing, analytical control, and regulatory review, translating antibody, linker, and payload choices into practical plans for conjugation, purification, containment, and release testing.
ADC development requires control of more than antibody quality alone. DAR distribution, conjugation-site heterogeneity, free payload, unconjugated antibody, aggregation, fragmentation, and linker stability can all influence batch consistency and filing readiness. Our teams build CMC plans around the attributes that matter most, using methods and control approaches that connect process decisions to product quality, from HIC-HPLC DAR assessment through impurity clearance and stability-indicating analytics.
ADC CMC Capabilities
Across IND-enabling, clinical, and commercial phases
Linker-Payload Selection
DAR Control & HIC-HPLC
Site-Specific Conjugation
Free Payload Analysis
Containment Strategy
ICH Q6B Specification Design
ICH Q14 / Q2(R2) Lifecycle
Our work spans preclinical development, IND-enabling work, clinical scale-up, tech transfer, process characterization, and commercial readiness planning. We help sponsors shape ADC programs around biologics specification expectations under ICH Q6B and current analytical lifecycle thinking under ICH Q14 and Q2(R2), while keeping the strategy practical, phase-appropriate, and ready for both internal decision-making and health authority review.
ADC CMC StrategyBuilt for the Complexity
of ADC Development
Every ADC program presents a unique intersection of antibody biology, synthetic chemistry, and biopharmaceutical manufacturing. Our teams bring deep experience across the critical control points that determine whether an ADC program advances on schedule, from early molecule design to a GMP-ready process.
Conjugation Process Development
Optimization of conjugation chemistry, reaction conditions, and scale-up parameters for both lysine and cysteine conjugation, as well as engineered site-specific approaches including unnatural amino acid and enzymatic platforms.
DAR Control & Analytical Strategy
Design of DAR distribution targets and control strategies using HIC-HPLC, RPLC-MS, and hydrophobic interaction methods. Alignment of analytical specifications with CMC filing requirements under ICH Q6B and evolving ADC characterization expectations.
Impurity & Free Payload Control
Development of methods for free drug, unconjugated antibody, linker-related impurities, and high-DAR species. Risk-based control strategies aligned with ICH Q3A/Q3B thresholds and potent compound safety considerations.
Containment & GMP Scale-Up
Planning for OEB-appropriate manufacturing environments, contained CDMO evaluation, potent compound handling SOPs, and engineering controls for clinical and commercial ADC manufacturing campaigns.
Regulatory CMC Strategy
Phase-appropriate CMC documentation, IND and BLA section development, Health Authority briefing books, and comparability strategies. Deep familiarity with FDA and EMA expectations for novel ADC modalities and combination product classifications.
Why DES Pharma Driving Results & Impact Real Results at Every Stage
End-to-End Development Support
Expertise across the entire drug product lifecycle, from preclinical IND planning through PPQ and commercial BLA filing.
Efficient, Results-Oriented Approach
Focused on essential experiments and decision-enabling data to accelerate program timelines and reduce development spend.
Robust Quality & Compliance
Ensuring product safety, batch integrity, and regulatory adherence at every stage of your program.
Ensuring product safety, batch integrity, and regulatory adherence at every stage of your program.
Dedicated expertise in potent compound GMP, DAR analytics, linker stability, and site-specific conjugation, beyond general biologics consulting.
Built on Science Built on Science, Focused on Safety
Reliable product quality begins with a strategic, system-driven development process. Our team at DES Pharma applies a disciplined program design that minimizes risk, streamlines operations, and protects patient safety.
For ADC programs, this means integrating potent compound controls, analytical lifecycle management, and risk-based CMC strategies into a single, cohesive development plan, aligned with current regulatory expectations from first-in-human through product approval.
InsightsNews & Blog Articles: Explore Recent Insights
Get Started
Advance Your ADC Program
with Confidence
Start building reliable, high-quality ADC development programs today.
Connect with our team to discuss your CMC strategy, analytical needs,
or supply chain requirements.



